Burden of Lung Cancer in China, 1990−2019: Findings from the Global Burden of Disease Study 2019

Background Lung cancer is one of the most common malignant tumors in the world. It has become an increasingly important public health problem in China. In this study, we systematically assessed the lung cancer situation in China from 1990 to 2019 and provided an epidemiological knowledge base for th...

Full description

Bibliographic Details
Main Authors: Huixin Sun, Haiyu Zhang, Huilong Cai, Weiguang Yuan, Fengjiao Wang, Yang Jiang, Xinyue Gu, Ziman Kang, Yue Kang
Format: Article
Language:English
Published: SAGE Publishing 2023-08-01
Series:Cancer Control
Online Access:https://doi.org/10.1177/10732748231198749
_version_ 1827820405198422016
author Huixin Sun
Haiyu Zhang
Huilong Cai
Weiguang Yuan
Fengjiao Wang
Yang Jiang
Xinyue Gu
Ziman Kang
Yue Kang
author_facet Huixin Sun
Haiyu Zhang
Huilong Cai
Weiguang Yuan
Fengjiao Wang
Yang Jiang
Xinyue Gu
Ziman Kang
Yue Kang
author_sort Huixin Sun
collection DOAJ
description Background Lung cancer is one of the most common malignant tumors in the world. It has become an increasingly important public health problem in China. In this study, we systematically assessed the lung cancer situation in China from 1990 to 2019 and provided an epidemiological knowledge base for the revision of health policies. The relevant data were extracted from the Global Burden of Disease (GBD) database. Methods Based on GBD 2019 data, we evaluated the incidence, prevalence, and death rates of lung cancer in China and their change trends from 1990 to 2019, making comparisons by gender and age. Results The age-standardized incidence and death rates (ASIR and ASDR, respectively) of lung cancer in China were higher than the average levels in Asia, Africa, Europe, and Oceania and also higher than those of neighboring Asian countries. Lung cancer rose from the seventh leading cause of death in 1990 to the fourth leading one in 2019, indicating that the disease burden of lung cancer is increasing. In 2019, the incidence, prevalence, and death rates of lung cancer were all higher in men than in women across all age groups. All three indices were lower in men and women <50 years old than in men and women >50 years. From 1990 to 2019, the ASIR, age-standardized prevalence rate (ASPR), and ASDR showed trends of increase ( P < .05), and the rise in the ASPR (average annual percentage change [AAPC] = 1.9) was greater than those in the ASIR (AAPC = 1) and ASDR (AAPC = .8). Conclusions From 1990 to 2019, the incidence, prevalence, and death rates of lung cancer continued to increase in China. To reduce this burden, prevention and management of known risk factors should be promoted through national policies.
first_indexed 2024-03-12T01:27:20Z
format Article
id doaj.art-79cc15bfb100460ebb825f18f9940cec
institution Directory Open Access Journal
issn 1526-2359
language English
last_indexed 2024-03-12T01:27:20Z
publishDate 2023-08-01
publisher SAGE Publishing
record_format Article
series Cancer Control
spelling doaj.art-79cc15bfb100460ebb825f18f9940cec2023-09-12T14:04:35ZengSAGE PublishingCancer Control1526-23592023-08-013010.1177/10732748231198749Burden of Lung Cancer in China, 1990−2019: Findings from the Global Burden of Disease Study 2019Huixin SunHaiyu ZhangHuilong CaiWeiguang YuanFengjiao WangYang JiangXinyue GuZiman KangYue KangBackground Lung cancer is one of the most common malignant tumors in the world. It has become an increasingly important public health problem in China. In this study, we systematically assessed the lung cancer situation in China from 1990 to 2019 and provided an epidemiological knowledge base for the revision of health policies. The relevant data were extracted from the Global Burden of Disease (GBD) database. Methods Based on GBD 2019 data, we evaluated the incidence, prevalence, and death rates of lung cancer in China and their change trends from 1990 to 2019, making comparisons by gender and age. Results The age-standardized incidence and death rates (ASIR and ASDR, respectively) of lung cancer in China were higher than the average levels in Asia, Africa, Europe, and Oceania and also higher than those of neighboring Asian countries. Lung cancer rose from the seventh leading cause of death in 1990 to the fourth leading one in 2019, indicating that the disease burden of lung cancer is increasing. In 2019, the incidence, prevalence, and death rates of lung cancer were all higher in men than in women across all age groups. All three indices were lower in men and women <50 years old than in men and women >50 years. From 1990 to 2019, the ASIR, age-standardized prevalence rate (ASPR), and ASDR showed trends of increase ( P < .05), and the rise in the ASPR (average annual percentage change [AAPC] = 1.9) was greater than those in the ASIR (AAPC = 1) and ASDR (AAPC = .8). Conclusions From 1990 to 2019, the incidence, prevalence, and death rates of lung cancer continued to increase in China. To reduce this burden, prevention and management of known risk factors should be promoted through national policies.https://doi.org/10.1177/10732748231198749
spellingShingle Huixin Sun
Haiyu Zhang
Huilong Cai
Weiguang Yuan
Fengjiao Wang
Yang Jiang
Xinyue Gu
Ziman Kang
Yue Kang
Burden of Lung Cancer in China, 1990−2019: Findings from the Global Burden of Disease Study 2019
Cancer Control
title Burden of Lung Cancer in China, 1990−2019: Findings from the Global Burden of Disease Study 2019
title_full Burden of Lung Cancer in China, 1990−2019: Findings from the Global Burden of Disease Study 2019
title_fullStr Burden of Lung Cancer in China, 1990−2019: Findings from the Global Burden of Disease Study 2019
title_full_unstemmed Burden of Lung Cancer in China, 1990−2019: Findings from the Global Burden of Disease Study 2019
title_short Burden of Lung Cancer in China, 1990−2019: Findings from the Global Burden of Disease Study 2019
title_sort burden of lung cancer in china 1990 2019 findings from the global burden of disease study 2019
url https://doi.org/10.1177/10732748231198749
work_keys_str_mv AT huixinsun burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019
AT haiyuzhang burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019
AT huilongcai burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019
AT weiguangyuan burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019
AT fengjiaowang burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019
AT yangjiang burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019
AT xinyuegu burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019
AT zimankang burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019
AT yuekang burdenoflungcancerinchina19902019findingsfromtheglobalburdenofdiseasestudy2019